Vir Biotechnology Inc (NASDAQ:VIR) currently has a daily average trading volume of 1.26M but it saw 2603766 shares traded in last market. With a market cap of 819.75M USD, the company’s current market price of $5.93 came rising about 11.89 while comparing to the previous closing price of $5.3. In past 52 weeks, the stock remained buoying in the range of price level as high as $14.45 and as low as $4.32. In the recent trading on the day, stock has struck highest price mark of $5.38 while lowest mark touched by it was $5.95.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the JP Morgan which downgraded the stock as “Neutral” in its note to investors issued on January 29, 2024, recommending a price target of between $23 and $9 for it. BofA Securities downgraded its recommendation for the stock as a “Neutral” from “Buy” on September 08, 2023 while assigning a price target range of $23-$14. JP Morgan issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $35 and $34.
Over the week, VIR’s stock price is moving 16.05% up while it is 8.81% when we observe its performance for the past one month. Year-to-date it is -30.48% down and over the past year, the stock is showing a downside performance of -19.21%.
The company is expected to be releasing its next quarterly report on 2025-May-07, for which analysts forecasted an EPS of -0.74 while estimate for next year EPS is -3.19. In next quarter, company is expected to be making quarterly sales of $2.38M as analysts are expecting the sales for current fiscal year at $16.91M and seeing the company making $16.48M in sales next year. Moreover, analysts are in estimates of $2.38M for current-quarter revenue.
Currently, Vir Biotechnology Inc’s total number of outstanding shares is 138.06M with 10.59% of that held by the insiders while 79.05% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -51.03% and return on equity (ROE) at -44.59%. Stock’s beta reads 1.18. Stock has a price to book (P/B) ratio of 0.78 while price to sale or P/S ratio amounts to 39.30. Its return on asset (ROA) is -37.25% on average.
